Patents by Inventor Nadége Arnaud-Barbe

Nadége Arnaud-Barbe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220265805
    Abstract: The present disclosure relates to an immunogenic composition comprising a combination of meningococcal antigens which comprises at least one factor H binding protein (fHBP) A protein, at least one fHBP B protein, at least one Neisseria adhesin A (NadA) protein, and at least one detergent-extracted Outer Membrane Vesicle (dOMV). The meningococcal antigens may be from a Neisseria meningitidis serogroup B. The combination of antigens provided a broad coverage of bacteria strains. Further, the present disclosure relates to the use of the immunogenic composition in methods for eliciting an immune response.
    Type: Application
    Filed: February 18, 2022
    Publication date: August 25, 2022
    Inventors: Nadège ARNAUD-BARBE, Vinod BALHARA, Raffaella IANTOMASI, Marie-Pierre KAZEK-DURET, Jacqueline MCCLUSKEY, Laurence QUEMENEUR, Bachra ROKBI, John SHIVER
  • Publication number: 20180125961
    Abstract: The present invention relates to novel polypeptides derived from Neisseria meningitidis proteins, in particular auto-transporters of the trypsin-like serine protease subclass, such as IgA1P, App and AusI, and their use in immunogenic compositions i.a., vaccine compositions for the prevention and/or treatment of meningococcal infections. In particular, it provides fragments of IgA1P, App and AusI and polypeptides comprising or consisting of these fragments and fusions thereof, which may be used in immunogenic compositions, for example vaccine compositions.
    Type: Application
    Filed: December 8, 2015
    Publication date: May 10, 2018
    Inventors: Nadège ARNAUD-BARBE, Geneviève RENAULD-MONGENIE, Bachra ROKBI
  • Publication number: 20180125960
    Abstract: The present invention relates to novel polypeptides derived from meningitis proteins, in particular auto-transporters of the subtilinase subclass, and their use in vaccines and vaccine compositions for the prevention and/or treatment of meningitis and meningococcal infections.
    Type: Application
    Filed: December 8, 2015
    Publication date: May 10, 2018
    Inventors: Nadège ARNAUD-BARBE, Geneviève RENAULD-MONGENIE, Bachra ROKBI
  • Patent number: 7595180
    Abstract: RNA may be transcribed using a nucleotide reagent as the promoter. The reagent may enable RNA to be transcribed without sequence specification and without protein cofactors, by means of an RNA polymerase that is known to be DNA-dependent such as the RNA polymerase of the phage T7, or by means of new, mutated RNA polymerase with the ability to synthesize a transcription product of polynucleotide matrix with a higher yield when the matrix is RNA than when the matrix is DNA. This type of RNA polymerase can be obtained by effecting mutations on a coding gene for a wild-type RNA polymerase, and then by selecting the mutated RNA polymerase with the ability. The invention can be applied notably to the detection, synthesis or quantification of RNA.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: September 29, 2009
    Assignee: Biomerieux
    Inventors: Valérie Cheynet-Sauvion, Nadège Arnaud-Barbe, Guy Oriol, William McAllister, Bernard Mandrand, François Mallet
  • Publication number: 20050069933
    Abstract: RNA may be transcribed using a nucleotide reagent as the promoter. The reagent may enable RNA to be transcribed without sequence specification and without protein cofactors, by means of an RNA polymerase that is known to be DNA-dependent such as the RNA polymerase of the phage T7, or by means of new, mutated RNA polymerase with the ability to synthesize a transcription product of polynucleotide matrix with a higher yield when the matrix is RNA than when the matrix is DNA. This type of RNA polymerase can be obtained by effecting mutations on a coding gene for a wild-type RNA polymerase, and then by selecting the mutated RNA polymerase with the ability. The invention can be applied notably to the detection, synthesis or quantification of RNA.
    Type: Application
    Filed: September 15, 2004
    Publication date: March 31, 2005
    Applicant: BIO MERIEUX
    Inventors: Valerie Cheynet-Sauvion, Nadege Arnaud-Barbe, Guy Oriol, William McAllister, Bernard Mandrand, Francois Mallet
  • Patent number: 6828127
    Abstract: Disclosed is a process for transcribing RNA using a nucleotide reagent as the promoter. Such a reagent enables any type of RNA to be transcribed without sequence specification and without protein cofactors, by means of an RNA polymerase that is known to be DNA-dependent such as the RNA polymerase of the phage T7, or by means of new, mutated RNA polymerase with the ability to synthesize a transcription product of a polynucleotide matrix with a higher yield when the matrix is RNA than when said matrix is DNA. This type of RNA polymerase can be obtained by effecting mutations on a coding gene for a wild-type RNA polymerase, and then by selecting the mutated RNA polymerase with said ability. The invention can be applied notably to the detection, synthesis or quantification of RNA.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: December 7, 2004
    Assignee: Bio Merieux
    Inventors: Valérie Cheynet-Sauvion, Nadége Arnaud-Barbe, Guy Oriol, William T. McAllister, Bernard Mandrand, François Mallet
  • Publication number: 20020119449
    Abstract: Disclosed is a process for transcribing RNA using a nucleotide reagent as the promoter. Such a reagent enables any type of RNA to be transcribed without sequence specification and without protein cofactors, by means of an RNA polymerase that is known to be DNA-dependent such as the RNA polymerase of the phage T7, or by means of new, mutated RNA polymerase with the ability to synthesize a transcription product of a polynucleotide matrix with a higher yield when the matrix is RNA than when said matrix is DNA. This type of RNA polvmerase can be obtained by effecting mutations on a coding gene for a wild-type RNA polvmerase and then by selecting the mutated RNA polymerase with said abilitv The invention can be applied notably to the detection, synthesis or quantification of RNA.
    Type: Application
    Filed: December 8, 1999
    Publication date: August 29, 2002
    Inventors: VALERIE CHEYNET-SAUVION, NADEGE ARNAUD-BARBE, GUY ORIOL, WILLIAM MCALLISTER, BERNARD MANDRAND, FRANCOIS MALLET